drug platform Articles
-
Beyond Fecal Microbiota Transplantation: Developing Drugs from the Microbiome
Abstract The transfer of live gut microbes may transform patient care across a range of autoimmune, metabolic, hepatic, and infectious diseases. One early approach, fecal microbiota transplantation, has shown promise in Clostridiodes difficile infection and the potential for improving clinical and public health outcomes for other antibiotic-resistant bacteria. These clinical successes have ...
-
The Liposome-Based PROTAC Strategy
Proteolysis Targeting Chimeras (PROTACs) are a novel approach for degrading target proteins. Recently, a new split-and-mix PROTAC (SM-PROTAC) system based on liposome self-assembly, known as LipoSM-PROTAC, was reported in the Journal of the American Chemical Society. The LipoSM-PROTAC system exhibits selective degradation of target proteins, with folate serving as a key ligand. In this study, the ...
By BOC Sciences
-
How much do animal models play a role in drug development?
Published by Vijay K Singh and Thomas M Seed on September 3, 2021, in Expert Opinion on Drug Discovery and deals with the necessity of animal models for modern drug research in the direction of animal strains, animal models, requirements, and pathways for developing new drugs. The use of experimental animal models in drug development aids in the understanding of disease and/or related conditions' ...
-
Looking to the Future of Neuro Devices: Exclusive Interview with Alcyone Lifesciences CEO PJ Anand
Alcyone Lifesciences is a medical technology company based out of Lowell, MA, which specializes in central nervous system (CNS) drug delivery platforms for targeted infusions of the brain or spinal cord. Their Thecaflex DRx System was recently awarded Breakthrough Device designation by the FDA, for spinal infusion of therapeutic medications. Medgadget had the opportunity to speak with Alcyone ...
-
In Silico Development of Combinatorial Therapeutic Approaches Targeting Key Signaling Pathways in Metabolic Syndrome
Purpose Dysregulations of key signaling pathways in metabolic syndrome are multifactorial, eventually leading to cardiovascular events. Hyperglycemia in conjunction with dyslipidemia induces insulin resistance and provokes release of proinflammatory cytokines resulting in chronic inflammation, accelerated lipid peroxidation with further development of atherosclerotic alterations and diabetes. We ...
By VeriSIM Life
-
Investigation into the Feasibility of a 2 mL Needle-Free Injector
The current paradigm of injectable drug delivery has stagnated since the early 2000s. Despite recent innovations, like the launch in Europe of the first electromechanical reusable and connected auto-injector (UCB’s CIMZIA ava Connect® in early 2021), almost all new biologic drugs are launched with specific and undifferentiated self-injection options: a spring-based ...
-
The Five Factors of Smart Laboratory Success
The Five Factors Research organizations are under pressure to cut costs while maintaining or increasing throughput. To improve their operations, many laboratories are considering investments in data management or support and automation systems like ELNs, LIMS or Robotics/HTS. Whatever the change that is introduced, there are many pitfalls on the way to delivery, roll-out and successful ...
-
Nanopharmaceuticals I: nanocarrier systems in drug delivery
To achieve maximum pharmacological effects with minimum side effects of drugs, drugs should be delivered to target sites without significant distribution to non-target areas. Using pharmaceutical nanocarrier systems for drug delivery is a useful delivery platform for improving target specificity, therapeutic activity, and reducing toxicity of drugs. Various sophisticated nanocarrier systems have ...
-
Predicting cardiotoxicity with engineered 3D human cardiac tissue models
Cardiovascular safety liabilities caused 52.3 % of 44 marketed data from 1980 to 2011, and cardiovascular disease remains the leading cause of death globally, yet only 8.7% of cardiovascular drugs successfully pass clinical trials. These statistics demonstrate the need to address a patient’s specific genetic make-up and phenotype by adopting a personalized treatment methodology for ...
-
Evaluating Microbiome Therapies with Intestinal Cell Models
The microbiome has been shown to play roles in many different disease processes and is implicated in many more, from infectious and gastrointestinal diseases to autoimmune and neurological disorders. Advanced models of the gut leveraging intestinal and colonic stem cells are enabling the development of more reliable and robust systems for evaluating the impact of changes in the microbiome on gut ...
-
Using AI to Fight a Pandemic: Insilico Medicine Announces Novel Preclinical Candidate for COVID-19 Treatment
Insilico Medicine announced the nomination of a novel preclinical therapeutic candidate for treating COVID-19, designed using the generative chemistry AI platform Chemistry42. The new drug candidate is a 3CL protease inhibitor unique from existing drugs in its class because it can be rapidly produced. While this nomination is a potentially important development for the ongoing COVID-19 pandemic ...
-
Increasing the Efficiency of Drug Development with Preclinical Testing Using Human Intestinal Stem Cells
Due to a lack of robust in vivo gut models, animal studies are generally required to evaluate gut toxicity. However, these studies can be lengthy and expensive and may not accurately recapitulate the behavior of the human gastrointestinal tract. Drugs are thus often developed with undesired gut side effects that are not apparent until clinical trials. Organ-on-a-chip models are the closest ...
-
A hybrid modeling approach for assessing mechanistic models of small molecule partitioning in vivo using a machine learning integrated modeling platform
Prediction of the first-in-human dosing regimens is a critical step in drug development and requires accurate quantitation of drug distribution. Traditional in vivo studies used to characterize clinical candidate’s volume of distribution are error-prone, time and cost intensive and lack reproducibility in clinical settings. The paper demonstrates how a computational platform integrating ...
By VeriSIM Life
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you